Yiwey Shieh

Yiwey Shieh

Auto-generated profile, based on publicly available information

Yiwey Shieh

Department of Population Health Sciences, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2009 in JAMA
Verified
Journal Article
Closed access
PDF file
LELaura Esserman
Laura Esserman
YSYiwey Shieh
Yiwey Shieh
ITIan Thompson
Ian Thompson
Review from JAMA — Rethinking Screening for Breast Cancer and Prostate Cancer

27 January 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
YSYiwey Shieh
Yiwey Shieh
MEMartin Eklund
Martin Eklund
LMLisa Madlensky
Lisa Madlensky
SSSarah D. Sawyer
Sarah D. Sawyer
CTCarlie K. Thompson
Carlie K. Thompson
JTJeffrey A. Tice
Jeffrey A. Tice
Ongoing controversy over the optimal approach to breast cancer screening has led to discordant professional society recommendations, particularly in women age 40 to 49 years. One potential solution is risk-based screening, where decisions around the starting age, stopping age, frequency, and modality of screening are based on individual risk to maximize the early detection of aggressive cancers and minimize the harms of screening through optimal resource utilization. We present a novel approach to risk-based screening that integrates clinical risk factors, breast density, a polygenic risk score representing the cumulative effects of genetic variants, and sequencing for moderate- and high-penetrance germline mutations. We demonstrate how thresholds of absolute risk estimates generated by our prediction tools can be used to stratify women into different screening strategies (biennial mammography, annual mammography, annual mammography with adjunctive magnetic resonance imaging, defer screening at this time) while informing the starting age of screening for women age 40 to 49 years. Our risk thresholds and corresponding screening strategies are based on current evidence but need to be tested in clinical trials. The Women Informed to Screen Depending On Measures of risk (WISDOM) Study, a pragmatic, preference-tolerant randomized controlled trial of annual vs personalized screening, will study our proposed approach. WISDOM will evaluate the efficacy, safety, and acceptability of risk-based screening beginning in the fall of 2016. The adaptive design of this trial allows continued refinement of our risk thresholds as the trial progresses, and we discuss areas where we anticipate emerging evidence will impact our approach.

26 August 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
YSYiwey Shieh
Yiwey Shieh
DHDonglei Hu
Donglei Hu
LMLin Ma
Lin Ma
SHScott Huntsman
Scott Huntsman
CGCharlotte C. Gard
Charlotte C. Gard
EZElad Ziv
Elad Ziv

13 April 2016 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YSYiwey Shieh
Yiwey Shieh
MEMartin Eklund
Martin Eklund
GSGeorge F. Sawaya
George F. Sawaya
WBWilliam C. Black
William C. Black
BKBarnett S. Kramer
Barnett S. Kramer
LELaura J. Esserman
Laura J. Esserman

9 March 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
EOElissa M. Ozanne
Elissa M. Ozanne
YSYiwey Shieh
Yiwey Shieh
JBJames Barnes
James Barnes
CBColleen Bouzan
Colleen Bouzan
EHE. Shelley Hwang
E. Shelley Hwang
LELaura J. Esserman
Laura J. Esserman

1 June 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
YSYiwey Shieh
Yiwey Shieh
LFLaura Fejerman
Laura Fejerman
PLPaul C Lott
Paul C Lott
KMKatie Marker
Katie Marker
SSSarah D Sawyer
Sarah D Sawyer
SNSusan L Neuhausen
Susan L Neuhausen
More than 180 single nucleotide polymorphisms (SNPs) associated with breast cancer susceptibility have been identified; these SNPs can be combined into polygenic risk scores (PRS) to predict breast cancer risk. Because most SNPs were identified in predominantly European populations, little is known about the performance of PRS in non-Europeans. We tested the performance of a 180-SNP PRS in Latinas, a large ethnic group with variable levels of Indigenous American, European, and African ancestry. We conducted a pooled case-control analysis of US Latinas and Latin American women (4658 cases and 7622 controls). We constructed a 180-SNP PRS consisting of SNPs associated with breast cancer risk (P < 5 × 10–8). We evaluated the association between the PRS and breast cancer risk using multivariable logistic regression, and assessed discrimination using an area under the receiver operating characteristic curve. We also assessed PRS performance across quartiles of Indigenous American genetic ancestry. All statistical tests were two-sided. Of 180 SNPs tested, 142 showed directionally consistent associations compared with European populations, and 39 were nominally statistically significant (P < .05). The PRS was associated with breast cancer risk, with an odds ratio per SD increment of 1.58 (95% confidence interval [CI = 1.52 to 1.64) and an area under the receiver operating characteristic curve of 0.63 (95% CI = 0.62 to 0.64). The discrimination of the PRS was similar between the top and bottom quartiles of Indigenous American ancestry. The 180-SNP PRS predicts breast cancer risk in Latinas, with similar performance as reported for Europeans. The performance of the PRS did not vary substantially according to Indigenous American ancestry.